**Helicobacter pylori** infection concomitant with metabolic syndrome further increase risk of colorectal adenomas

Ying-Lung Lin, Jui-Kun Chiang, Shih-Min Lin, Chih-En Tseng

**Abstract**

**AIM:** To investigate the association of colorectal adenomas with both **Helicobacter pylori** (H. pylori) infection and metabolic syndrome.

**METHODS:** Using a cross-sectional hospital-based study, we analyzed physical examination data from 9311 healthy subjects with overnight physical examinations performed between January 2004 and December 2006. Examined data included gender, age, life style, anthropometric measurements, blood pressure, biochemical and hematological studies, H. pylori infection detected by esophagogastroduodenoscopy and biopsy urease tests, and colorectal adenomas detected with a complete total colonoscopy.

**RESULTS:** The prevalence values for H. pylori infection, metabolic syndrome, and colorectal adenoma were 39.2%, 18.7%, and 20.7%, respectively. Colorectal adenoma risk factors included male gender (odds ratio (OR): 2.005, 95% confidence interval (CI): 1.740-2.310, \( P < 0.001 \)), advanced age (OR: 1.046, 95% CI: 1.040-1.052, \( P < 0.001 \)), smoking (OR: 1.377, 95% CI: 1.146-1.654, \( P = 0.001 \)), increased body fat (OR: 1.016, 95% CI: 1.007-1.026, \( P = 0.001 \)), higher white blood cell count (OR: 1.038, 95% CI: 1.005-1.073, \( P = 0.025 \)), H. pylori infection (OR: 1.366, 95% CI: 1.230-1.517, \( P < 0.001 \)), and metabolic syndrome (OR: 1.408, 95% CI: 1.231-1.610, \( P < 0.001 \)). In addition, concomitant H. pylori infection with metabolic syndrome further increased the probability of colorectal adenomas.

**CONCLUSION:** Our study revealed H. pylori infection with concomitant metabolic syndrome might further increase the risk of colorectal adenomas.

© 2010 Baishideng. All rights reserved.

**Key words:** Biopsy urease test; Colorectal adenoma; Colorectal cancer; Helicobacter pylori; Metabolic syndrome

**Peer reviewer:** Dr. Charles B Ferguson, MRCP, Department of Gastroenterology, Belfast City Hospital, 51 Lisburn Road, Belfast, BT9 7AB, United Kingdom

Lin YL, Chiang JK, Lin SM, Tseng CE. **Helicobacter pylori** infection concomitant with metabolic syndrome further increase risk of colorectal adenomas. *World J Gastroenterol* 2010; 16(30): 3841-3846 Available from: URL: http://www.wjgnet.com/1007-9327/full/v16/i30/3841.htm DOI: http://dx.doi.org/10.3748/wjg.v16.i30.3841
through the adenoma-to-carcinoma sequence\(^1\). The direct etiology of colorectal neoplasms is still unknown. However, previous epidemiological studies have identified family history, dietary factors, smoking, sedentary lifestyles, and alcohol consumption as potential contributors to colorectal neoplasm development\(^2\). Identification of the etiology of colorectal neoplasms might assist in the development of strategies targeted toward its prevention.

*Helicobacter pylori* (*H. pylori*) is a human pathogen that infects the gastric mucosa and causes inflammatory process that culminates in chronic gastritis, peptic ulceration, gastric lymphoma of mucosa-associated lymphoid tissue, and adenocarcinoma\(^3\). *H. pylori* is a gram-negative microaerophilic bacillus, and has been classified by the International Agency for Research on Cancer as a class 1 human carcinogen since 1994\(^4\). The role of *H. pylori* in colorectal carcinogenesis has been epidemiologically examined in recent decades; however, the association has remained inconclusive. Several studies have identified an association between *H. pylori* infection and colorectal neoplasms\(^5\)-\(^9\), while others have identified a negative association between the two\(^10\)-\(^12\). Methodological issues might account for some of the inconsistent results, including the IgG serum antibody test and incomplete colonoscopic examinations for diagnosis.

Metabolic syndrome is a clinical cluster of metabolic abnormalities. It is also referred to as insulin resistance syndrome, and is diagnosed by criteria corresponding to the modified National Cholesterol Education Program (NCEP) criteria\(^13\). Diagnosis is fulfilled by the presence of any three of the following conditions: higher waist circumference (\(\geq 90\) cm in men and \(\geq 80\) cm in women), elevated triglycerides (\(\geq 150\) mg/dL), lower high density lipoprotein cholesterol (< 40 mg/dL in men and < 50 mg/dL in women), elevated blood pressure (systolic blood pressure \(\geq 130\) mmHg or diastolic blood pressure \(\geq 85\) mmHg), and elevated fasting glucose (\(\geq 100\) mg/dL). This syndrome might be a risk factor for type 2 diabetes and cardiovascular disease\(^14\),\(^15\). In recent years, metabolic syndrome has also been associated with an increased risk of colorectal adenoma. However, there is very limited medical literature examining the relationship between colorectal adenoma and metabolic syndrome\(^16\)-\(^18\). Additional information on the correlation between metabolic syndrome and colorectal neoplasms could result in the recommendation for screening of colorectal neoplasms in the patient with metabolic syndrome.

Using a cross-sectional hospital-based study, we investigated the association of colorectal adenoma with both *H. pylori* infection and metabolic syndrome. Further, the probability of colorectal adenoma in patients with both *H. pylori* infection and metabolic syndrome was evaluated.

**MATERIALS AND METHODS**

A total of 11787 asymptomatic subjects were admitted to the general physical examination department of the Budhist Dalin Tzu-Chi General Hospital for general check-ups (two-day health examination) between January 2004 and December 2006. Excluding 2476 subjects aged below 40 years, a final total of 9311 study participants (3906 males and 5405 females) were enrolled in the study. The demographic data included age, gender, medical past history, and lifestyle. Clinical data included blood pressure, fasting plasma sugar, plasma lipids levels (total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, and triglycerides), and hematological variables. Anthropometric measurements including height (meters), weight (kilograms), and body fat (percent; Body Composition Analyzer TBF-410, Tanita, Japan) were also examined.

Metabolic syndrome was diagnosed with the modified NCEP criteria. *H. pylori* infection was detected by the biopsy urease test (CLO test, Pronto Dry, Gastrex, Poland) using standard video esophagogastroduodenoscopy (EGD) with gastrofibroscopes (GIFXP-240, GIFQ260, Olympus Optical, Tokyo Japan). A specimen for biopsy urease testing of each subject was taken from the gastric antrum using biopsy forceps and assessed within 60 min. The agar color of the biopsy urease test turned from yellow to red when the biopsy specimen was infected with *H. pylori*, which contained intracytoplasmic urease. Colorectal adenomas were identified by complete total colonoscopy using standard video colonoscopes (CF 240I, Olympus Optical, Tokyo, Japan) by single- and double-handed methods under intravenous 1% Propofol (Fresenius Kabi, Austria). This study was performed under the approval of our hospital Institutional Review Board.

**Statistical analysis**

Data for continuous variables were expressed as mean ± SD. The *t* test was applied for continuous variables when the data fitted a Gaussian distribution. If the continuous data did not fit the Gaussian distribution, the Wilcoxon rank sum test was applied. Categorical variables were tested with the *χ*\(^2\) test. Stepwise logistic regression analysis was conducted for significant variable selection. Basic model-fitting techniques for regression analysis were applied to assure the quality of analysis results, including variable selection, goodness-of-fit assessment, and regression diagnostics. Statistical significance was established for two-sided *P* values < 0.05. All statistical analyses were performed with the SAS\(^®\) software, version 9.1.3 (SAS Institute Inc., Cary, NC, USA) and R 2.6.2 (R Development Core Team, R Foundation for Statistical Computing, 2008, Vienna, Austria).

**RESULTS**

The median ages of the study participants were 54 years in males and 52 years in females. All subjects went through complete EGD examination, and 2.8% of participants had incomplete colonoscopy examination. The raw prevalence rates of *H. pylori* infection, metabolic syndrome, and colorectal adenoma were 39.2%, 18.7% and 20.7%,
respectively. A total of 1923 adenomas, including 1691 tubular adenomas, 208 tubulovillous adenomas, and 24 serous adenomas, were detected. Males were significantly older (P < 0.001), were more likely to smoke (P < 0.001), drink alcohol (P < 0.001), have heavier body weight (P < 0.001), lesser body fat (P < 0.001), and higher systolic and diastolic blood pressure values (P < 0.001). Males additionally had a higher proportion of hypertension (P < 0.001), diabetes (P < 0.001), higher fasting blood glucose levels (P < 0.001), higher white blood cell (WBC) counts (P < 0.001), lower lymphocyte percentages (P < 0.001), and a higher prevalence of colorectal adenoma (P < 0.001). There were no significant differences in total plasma cholesterol levels (P = 0.448), metabolic syndrome frequency (P = 0.154), and H. pylori infection frequency (P = 0.096) between males and females (Table 1).

Multivariate logistic regression analysis revealed that male gender (OR: 2.005; 95% confidence interval (CI), 1.740-2.310, P < 0.001), advanced age (OR: 1.046, 95% CI: 1.040-1.052, P < 0.001), smoking (OR: 1.377, 95% CI: 1.146-1.654, P = 0.001), increased body fat (OR: 1.016, 95% CI: 1.007-1.026, P = 0.001), higher white blood cell (WBC) count (OR: 1.038, 95% CI: 1.005-1.073, P = 0.025), H. pylori infection (OR: 1.366, 95% CI: 1.230-1.517, P < 0.001), and metabolic syndrome (OR: 1.408, 95% CI: 1.231-1.610, P < 0.001) were associated risk factors for colorectal adenoma. Alcohol consumption (OR: 0.990, 95% CI: 0.826-1.187, P = 0.915) was not a risk factor for colorectal adenoma (Table 2). Under analysis with a conditional effect plot, colorectal adenoma risk was positively associated with WBC count among paired groups of positive and negative H. pylori-infected patients and paired groups of positive and negative metabolic syndrome patients (Figure 1).

**DISCUSSION**

The results of our study supported the association of H. pylori infection with colorectal adenomas and were consistent with previous reports that metabolic syndrome might increase colorectal adenoma risk. It also showed that individuals with concomitant metabolic syndrome and H. pylori infection might have a further increased risk of colorectal adenomas.

The inconclusive results of previous studies concerning the relationship between H. pylori infection and colorectal neoplasm might have been due to sample bias, small sample size, inadequate consideration of potential confounding variables, and a varying frequency of cag A+ strains in the study populations. In addition, incomplete colonoscopic studies and evaluation of H. pylori infection with the IgG serum test (which cannot represent real-time H. pylori infection) might also have contributed to the inconsistent results. The advantages of our study include large sample size, detection of H. pylori infection with the EGD and biopsy CLO test, and complete colonoscopic studies and evaluation of colorectal adenoma. The inconclusive results of previous studies concerning the relationship between H. pylori infection and colorectal neoplasm might have been due to sample bias, small sample size, inadequate consideration of potential confounding variables, and a varying frequency of cag A+ strains in the study populations. In addition, incomplete colonoscopic studies and evaluation of H. pylori infection with the IgG serum test (which cannot represent real-time H. pylori infection) might also have contributed to the inconsistent results. The advantages of our study include large sample size, detection of H. pylori infection with the EGD and biopsy CLO test, and complete colonoscopic studies and evaluation of colorectal adenoma.
However, there were also some limitations in our study. Patients in the study were selected from a population who sought routine physical examinations at our institute, and their psychosocial behaviors and lifestyle habits might differ from those in the general population, resulting in a confounding bias that could be ignored in the data analysis. Although *H. pylori* infection can be more accurately detected by biopsy CLO test than by the serum IgG method logically, in rare instances antral biopsies with CLO tests might not be representative of all gastric states of *H. pylori* infection. In addition, past historical data of diagnosis and treatment of *H. pylori* infection were not included in the analysis, although the enrolled cases were clinically asymptomatic. Additionally, blood insulin, gastrin levels, and proinflammatory cytokines were not measured. The study design also did not allow the identification of the pathologic mechanisms underlying the association of colorectal adenoma with metabolic syndrome and *H. pylori* infection.

The pathogenic mechanisms by which *H. pylori* exerts its malignant potential in the induction of colorectal neoplasms are not completely understood. A few studies have revealed that fecal shedding of viable *H. pylori* and its antigen occurs under certain circumstances[21,24], suggesting that *H. pylori* moves through the intestinal tract in direct contact with colonic mucosa, and could therefore locally activate colonic carcinogenesis. *H. pylori* was recently detected within colorectal carcinoma tissues[23]. The role of *H. pylori*-specific affinity for colorectal neoplasms requires further investigation. The presence of *H. pylori* might alter normal gastrointestinal flora as a consequence of progressive chronic gastritis with glandular atrophy and decreased acid production. This could further influence colorectal carcinogenesis. Persistent *H. pylori* exposure induces hypergastrinemia, which is a putative trophic factor for the large bowel mucosa. Cell proliferation and gastrin-induced genomic instability can increase the risk of DNA replication error and play a role in the development of colorectal neoplasms[25]. *H. pylori* infection might also result in direct damage to the colorectal mucosa or indirect damage to the epithelium through inflammatory responses. Contact between a repaired epithelium and endogenous or dietary carcinogens within the gut might transform the colorectal mucosa[25]. The CagA protein is the product of the cytotoxin-associated gene and is produced by cagA+ strains of *H. pylori*. It might locally activate colonic carcinogenesis through the induction of cytokine expression, including cytokines such as interleukin (IL)-8, which is associated with colorectal cancer[26]. In summary, *H. pylori* might result in local and distant interactions with colorectal mucosa and contribute to the pathogenesis of malignant transformation. However, further mechanistic studies are required.

Metabolic syndrome and its association with colorectal adenomas have been the subjects of recent study, and the pathogenic mechanisms for this potential association are still unclear. Insulin (a core contributor to metabolic syndrome) has been demonstrated to promote colorectal carcinogenesis in animal studies for more than 10 years[27,28]. It is postulated that insulin might exert proliferative effects on colonic tumor cells directly or indirectly via the insulin-like growth factor pathway[28]. Furthermore, increased production of proinflammatory cytokines and decreased production of anti-inflammatory adiponectin in adipocytes might be related to adenoma growth. In addition, hypertriglyceridemia (a component of metabolic syndrome) might be involved in colorectal neoplasm pathogenesis. Triglycerides act as potent energy sources for cancer cell growth, and elevated serum triglyceride levels have been associated with increased synthesis of bile acids, which could promote large bowel carcinogenesis, as demonstrated in experimental studies[29]. Metabolic syndrome is associated with chronic inflammation, which might explain its possible association with colorectal adenoma. Adipose tissue and circulating levels of inflammatory cytokines [including tumor necrosis factor (TNF)-α and IL-6] are increased in obese and diabetic patients, and can induce several metabolic derangements characteristic of metabolic syndrome[30,31]. IL-6-induced C-reactive protein (CRP) might predict colon cancer occurrence; meanwhile, an elevated CRP level is a consistent feature of metabolic syndrome[32]. The findings indicate that chronic inflammation might be associated with colorectal carcinogenesis. In short, these evidence-base data suggest that metabolic syndrome might be a risk factor for colorectal neoplasm development.

In this study, concomitant with *H. pylori* infection and metabolic syndrome might further increase the risk of developing colorectal adenoma. The concomitant effect of metabolic syndrome and *H. pylori* infection might occur secondary to common inflammatory pathways of colorectal pathologic mechanisms associated with metabolic syndrome and *H. pylori* infection. The inflammation-related factors of metabolic syndrome include IL-6, TNF-α, fibrinogen, and cyclooxygenase-2. The inflammation-related factors of *H. pylori* including IL-8, TNF-α, and the Cag A, Vac A, and babA2 proteins might display similar inflammatory effects attributable to the common inflammatory pathway. White blood cell counts are a risk factor of colorectal adenoma in the multivariate logistic regression analysis and might support this hypothesis of the involvement of the common inflammatory pathway. However, further investigations on the pathogenesis of this concomitant effect are necessary. Clinically, our results suggested that both *H. pylori* infection and metabolic syndrome should both be evaluated for the prevention of colorectal adenomas and carcinomas.

Studies have revealed that moderate alcohol consumption is related to increased insulin-sensitivity[33], while smoking exerted the opposite effect[34]. Other studies have suggested that both alcohol use and cigarette smoking were associated with increased risk of colorectal adenoma[35,36]. Cigarette smoking was related to colorectal adenomas in this study, although alcohol consumption was not. To clarify the association between alcohol consumption and colorectal adenoma, further studies are necessary.

In conclusion, this cross-sectional hospital-based study revealed a direct association of colorectal adenoma with *H. pylori* infection and metabolic syndrome. Furthermore, *H. pylori* infection concomitant with metabolic syndrome...
might further increase the risk of colorectal adenoma. These results suggest that both *H. pylori* infection and metabolic syndrome should be considered important entities with regards to the prevention of colorectal adenoma and carcinoma. This is particularly important when a patient clinically presents with concomitant *H. pylori* infection and metabolic syndrome. The combined effects of metabolic syndrome and *H. pylori* infection should be further clarified.

ACKNOWLEDGMENTS

The authors greatly appreciate the financial and technical support of Dalin Tzu Chi General Hospital, and the help of the President of the School of Medicine of Japan Jichi Medical University, Professor Fumimaro Takaku, who kindly revised the manuscript.

REFERENCES

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767
2. Giovannucci E. Modifiable risk factors for colon cancer. *Gastroenterology Clin North Am* 2002; 31: 925-943
3. Rothenbacher D, Brenner H. Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications. *Microbes Infect* 2003; 5: 693-703
4. Infection with Helicobacter pylori. In: World Health Organization. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 61. Schistosomes, liver flukes and Helicobacter pylori. Lyon: France: International Agency for Research on Cancer. 1994; 177-240
5. Meucci G, Tatarrella M, Vecchi M, Ranzi ML, Biguzzi E, Beccari G, Clerici E, de Franchis R. High prevalence of Helicobacter pylori infection in patients with colonic adenomas and carcinomas. *J Clin Gastroenterol* 1997; 25: 605-607
6. Breuer-Katschinski B, Nemes K, Marr A, Rump B, Leendecker B, Breuer N, Goebell H. Helicobacter pylori and the risk of colonic adenomas. Colorectal Adenoma Study Group. *Digestion* 1999; 60: 210-215
7. Mizuno S, Morita Y, Inui T, Asakawa A, Ueno N, Ando T, Kato H, Uchida M, Yoshikawa T, Inui A. Helicobacter pylori infection is associated with colon adenomatous polyps detected by high-resolution colonoscopy. *Int J Cancer* 2005; 117: 1058-1059
8. Fujimori S, Kishida T, Kobayashi T, Sekita Y, Seo T, Nagata K, Tatsuguchi A, Gudis K, Yokoi K, Tanaka N, Yamashita K, Tajiri T, Ohaki Y, Sakamoto C. Helicobacter pylori infection increases the risk of colorectal adenoma and adencarcinoma, especially in women. *J Gastroenterol* 2005; 40: 887-893
9. Zumkeller N, Brenner H, Zwahlen M, Rothenbacher D. Helicobacter pylori infection and colorectal cancer risk: a meta-analysis. *Helicobacter* 2006; 11: 75-80
10. Siddheshwar RK, Muhammad KB, Gray JC, Kelly SB. Seroprevalence of Helicobacter pylori in patients with colorectal polyps and colorectal carcinoma. *Am J Gastroenterol* 2001; 96: 84-88
11. Limburg PJ, Stolzenberg-Solomon RZ, Colbert LH, Perez-Perez GI, Blaser MJ, Taylor PR, Virtamo J, Albanes D. Helicobacter pylori seropositivity and colorectal cancer risk: a prospective study of male smokers. *Cancer Epidemiol Biomarkers Prev* 2002; 11: 1095-1099
12. Granh N, Hmani-Aifa M, Fransén K, Söderkvist P, Monstein HJ. Molecular identification of Helicobacter DNA present in human colorectal adenocarcinomas by 16S rDNA PCR amplification and pyrosequencing analysis. *J Med Microbiol* 2005; 54: 1031-1035
13. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? *Diabetes Care* 2004; 27: 1182-1186
14. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. *Diabetes Care* 1998; 21: 1414-1431
15. Haslam DW, James WP. Obesity. *Lancet* 2005; 366: 1197-1209
16. Morita T, Tabata S, Mineshita M, Mizoue T, Moore MA, Kono S. The metabolic syndrome is associated with increased risk of colorectal adenoma development: the Self-Defense Forces health study. *Asian Pac J Cancer Prev* 2005; 6: 485-489
17. Wang YY, Lin SY, Lai WA, Liu PH, Sheu WH. Association between adenomas of rectosigmoid colon and metabolic syndrome features in a Chinese population. *J Gastroenterol Hepatol* 2005; 20: 1410-1415
18. Kim JH, Lim YJ, Kim YH, Sung IK, Shim SG, Oh SO, Park SS, Yang S, Son HJ, Rhee PL, Kim JJ, Rhee JC, Choi YH. Is metabolic syndrome a risk factor for colorectal adenoma?
Lin YL et al. H. pylori and MS risk colorectal adenoma

Cancer Epidemiol Biomarkers Prev 2007; 16: 1543-1546

19 Shmuely H, Passaro D, Figer A, Niv Y, Pitlik S, Samra Z, Koren R, Yahav J. Relationship between Helicobacter pylori CagA status and colorectal cancer. Am J Gastroenterol 2001; 96: 3406-3410

20 Takeda H, Asaka M. Helicobacter pylori and colorectal neoplasms: a mysterious link? J Gastroenterol 2005; 40: 919-920

21 Thomas JE, Gibson GR, Darboe MK, Dale A, Weaver LT. Isolation of Helicobacter pylori from human faeces. Lancet 1992; 340: 1194-1195

22 Parsonnet J, Shmuely H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA 1999; 282: 2240-2245

23 Jones M, Helliswell P, Pritchard C, Tharakan J, Mathew J. Helicobacter pylori in colorectal neoplasms: is there an aetiological relationship? World J Surg Oncol 2007; 5: 51

24 Ames BN, Gold LS. Too many rodent carcinogens: mitogenesis increases mutagenesis. Science 1990; 249: 970-971

25 Parsonnet J. Bacterial infection as a cause of cancer. Environ Health Perspect 1995; 103 Suppl 8: 263-268

26 Brew R, Erikson JS, West DC, Kinsella AR, Slavin J, Christmas SE. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine 2000; 12: 78-85

27 Tran TT, Medline A, Bruce WR. Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 1996; 5: 1013-1015

28 Corpet DE, Jacquinet C, Peiffer G, Taché S. Insulin injections promote the growth of aberrant crypt foci in the colon of rats. Nutr Cancer 1997; 27: 316-320

29 Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-1489

30 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428

31 Moller DE, Flier JS. Insulin resistance–mechanisms, syndromes, and implications. N Engl J Med 1991; 325: 938-948

32 Hill MJ. Bile flow and colon cancer. Mutat Res 1990; 238: 313-320

33 Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatani K, Yano Y. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998; 83: 859-862

34 Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745-E751

35 Erlinger TP, Platt EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291: 585-590

36 Davies MJ, Baer DJ, Judd JT, Brown ED, Campbell WS, Taylor PR. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. JAMA 2002; 287: 2559-2562

37 Facchini FS, Hollenbeck CB, Jeffesen J, Chen YD, Reaven GM. Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128-1130

38 Giovannucci E, Martinez ME. Tobacco, colorectal cancer, and adenomas: a review of the evidence. J Natl Cancer Inst 1996; 88: 1717-1730

39 Toyomura K, Yamaguchi K, Kawamoto H, Tabata S, Shimizu E, Mineshita M, Ogawa S, Lee KY, Kono S. Relation of cigarette smoking and alcohol use to colorectal adenomas by subsite: the self-defense forces health study. Cancer Sci 2004; 95: 72-76